-
摘要:
目的 探讨应用感染性供者器官的安全性。 方法 回顾性分析67例行同种异体原位肝移植术的供、受者临床资料。根据供者是否存在感染及感染部位将受者分为3组, 血流感染组(供者非耐药菌感染, 16例)、非血流感染组(供者血流以外部位存在感染, 20例)和未感染组(31例)。比较3组受者围手术期临床指标, 包括术前终末期肝病模型(MELD)评分、手术时间、无肝期、术中出血量、术中输血量; 观察受者术后1、3、7、14、21 d肝功能及凝血功能恢复情况; 记录受者肝移植术后1个月内的并发症发生率及病死率; 观察受者术后感染指标恢复情况, 包括白细胞(WBC)、中性粒细胞百分比(NE%)、降钙素原(PCT)。记录受者限制级别抗生素应用率及应用时间。 结果 3组受者围手术期临床指标的差异均无统计学意义(均为P > 0.05)。3组受者术后各时间点的肝功能、凝血功能、并发症发生率及病死率差异均无统计学意义(均为P > 0.05)。血流感染组受者术后3、7 d的NE%明显高于非血流感染组和未感染组受者(均为P < 0.05), 血流感染组受者术后3、7、14 d的PCT明显高于非血流感染组和未感染组受者(均为P < 0.05)。血流感染组受者的限制级抗生素使用率、使用时间均明显高于或长于非血流感染组和未感染组受者(均为P < 0.05)。 结论 在尽早应用抗生素的前提下, 应用非耐药菌血流感染或其他局部感染捐献者的供肝是安全的。 Abstract:Objective To explore the safety application of organs from infectious donors. Methods Clinical data of 67 donors and recipients undergoing orthotopic liver transplantation were retrospectively analyzed. According to the occurrence of infections and infection sites in donors, all recipients were divided into the bloodstream infection group (n=16, donors with non-drug resistant bacterial infections), non-bloodstream infection group (n=20, donors with other site infections) and non-infection group (n=31). Perioperative clinical parameters including preoperative model for end-stage liver disease (MELD) score, operative time, anhepatic phase, intraoperative blood loss and intraoperative blood transfusion were statistically compared among three groups. The recovery of liver function and coagulation function in the recipients was observed at postoperative 1, 3, 7, 14 and 21 d. The incidence rate of complications and mortality rate in the recipients were recorded within 1 month after liver transplantation. The recovery of postoperative infection-related parameters including white blood cell (WBC), neutrophil pet (NE%) and procalcitonin (PCT) level in the recipients was observed. The application rate and application time of restricted antibiotics were recorded. Results Perioperative clinical parameters in the recipients did not significantly differ among three groups (all P > 0.05). At each time point after liver transplantation, the liver function, coagulation function, incidence rate of complications and mortality rate in the recipients did not significantly differ among three groups (all P > 0.05). The NE% of recipients at postoperative 3 and 7 d in the bloodstream infection group was significantly higher than those in non-bloodstream infection and non-infection groups (all P < 0.05). The PCT levels of recipients at postoperative 3, 7 and 14 d in the bloodstream infection group were significantly higher than those in the non-bloodstream infection and non-infection groups (all P < 0.05). The application rate and application time of restricted antibiotics in the recipients with bloodstream infections were significantly higher or longer than their counterparts in the non-bloodstream infection and non-infection groups (all P < 0.05). Conclusions It is safe to apply liver grafts from donors with bloodstream infection of non-drug resistant bacteria or other site infections when antibiotics are applied as early as possible. -
表 1 3组肝移植受者围手术期情况比较
Table 1. Comparison of perioperative status of liver transplantation recipients among 3 groups
组别 n MELD评分
[M(R), 分]手术时间
(x±s, min)无肝期
(x±s, min)术中出血量
[M(R), mL]术中输血量
[M(R), mL]血流感染组 16 10(33) 482±58 69±11 1 200(3 100) 1 200(4 000) 非血流感染组 20 8(42) 496±82 69±9 1 500(4 400) 1 600(4 000) 未感染组 31 9(40) 498±79 68±7 1 600(4 600) 1 600(3 600) 统计值 0.194 0.245 0.210 1.098 0.601 P值 0.824 0.784 0.811 0.340 0.552 表 2 3组肝移植受者术后1个月并发症及死亡情况
Table 2. Complications and death of liver transplant recipients in 3 groups within 1 month after operation[n(%)]
组别 n ARDS AKI DGF 感染 死亡 血流感染组 16 2(13) 3(19) 2(13) 6(38) 2(13) 非血流感染组 20 2(10) 2(10) 3(15) 4(20) 1(5) 未感染组 31 4(13) 5(16) 4(13) 4(13) 1(3) P值 0.897 0.937 0.947 0.263 0.435 -
[1] WOLACH B, SAZBON L, GAVRIELI R, et al. Early immunological defects in comatose patients after acute brain injury[J]. J Neurosurg, 2001, 94(5):706-711. doi: 10.3171/jns.2001.94.5.0706 [2] MOHAREM HA, FETOUH FA, DARWISH HM, et al. Effects of bacterial translocation on hemodynamic and coagulation parameters during living-donor liver transplant[J]. BMC Anesthesiol, 2018, 18(1):46. DOI: 10.1186/s12871-018-0507-7. [3] CHONG PP, RAZONABLE RR. Diagnostic and management strategies for donor-derived infections[J]. Infect Dis Clin North Am, 2013, 27(2):253-270. DOI: 10.1016/j.idc.2013.02.001. [4] LEWIS JD, SIFRI CD. Multidrug-resistant bacterial donor-derived infections in solid organ transplantation[J]. Curr Infect Dis Rep, 2016, 18(6):18. DOI: 10.1007/s11908-016-0526-9. [5] HU FP, GUO Y, ZHU DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014[J]. Clin Microbiol Infect, 2016, 22(Suppl 1): S9-S14. DOI: 10.1016/j.cmi.2016.01.001. [6] VAN DUIN D, VAN DELDEN C, AST Infectious Diseases Community of Practice. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4): 31-41. DOI: 10.1111/ajt.12096. [7] GOLDBERG E, BISHARA J, LEV S, et al. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report[J]. Transpl Infect Dis, 2012, 14(3):296-299. DOI: 10.1111/j.1399-3062. 2011.00697.x. [8] SIMKINS J, MUGGIA V. Favorable outcome in a renal transplant recipient with donor-derived infection due to multidrug-resistant pseudomonas aeruginosa[J]. Transpl Infect Dis, 2012, 14(3):292-295. DOI: 10.1111/j.1399-3062.2011.00674.x. [9] SINGH N, HUPRIKAR S, BURDETTE SD, et al. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice[J]. Am J Transplant, 2012, 12(9):2414-2428. DOI: 10.1111/j.1600-6143.2012.04100.x. [10] 丁利民, 徐志丹, 李新长, 等.公民逝世后器官捐献供肝保护及功能评估临床分析[J].器官移植, 2017, 8(6):430-434. DOI: 10.3969/j.issn.1674-7445.2017.06.004.DING LM, XU ZD, LI XC, et al. Clinical analysis on donor liver protection and function evaluation for organ donation after citizen' s death[J]. Organ Transplant, 2017, 8(6):430-434. DOI:10.3969/j.issn. 1674-7445.2017.06.004. [11] NELLORE A, FISHMAN JA. Donor-derived infections and infectious risk in xenotransplantation and allotransplantation[J]. Xenotransplantation, 2018, 25(4):e12423. DOI: 10.1111/xen.12423. [12] BENAMU E, WOLFE CR, MONTOYA JG. Donor-derived infections in solid organ transplant patients: toward a holistic approach[J]. Curr Opin Infect Dis, 2017, 30(4):329-339. DOI: 10.1097/QCO.0000000000000377. [13] FISCHER SA. Is this organ donor safe?: donor-derived infections in solid organ transplantation[J]. Infect Dis Clin North Am, 2018, 32(3):495-506. DOI: 10.1016/j.idc.2018.04.001. [14] 王婷婷, 孔心涓, 饶伟.边缘性供肝移植术后早期肝功能不全影响因素的研究进展[J/CD].实用器官移植电子杂志, 2016, 4(5): 302-305. DOI: 10.3969/j.issn.2095-5332.2016.05.010.WANG TT, KONG XJ, RAO W, et al. Research progress on factors affecting early liver dysfunction after marginal donor liver transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2016, 4(5): 302-305. DOI: 10.3969/j.issn.2095-5332.2016.05.010. [15] PITOUT JD, NORDMANN P, POIREL L. Carbapenemase- producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance[J]. Antimicrob Agents Chemother, 2015, 59(10):5873-5884. DOI:10.1128/AAC. 01019-15. [16] 中华医学会器官移植学分会, 中华预防医学会医院感染控制学分会, 复旦大学华山医院抗生素研究所.中国实体器官移植供者来源感染防控专家共识(2018版)[J].中华器官移植杂志, 2018, 39(1):41-52. DOI: 10.3760/cma.j.issn.0254-1785.2018.01.008.Branch of Organ Transplantation of Chinese Medical Association, Branch of Nosocomial Infection Control of Chinese Preventive Medical Association, Antibiotic Research Institute of Fushan University Huashan Hospital. Expert consensus on prevention and control of Chinese solid organ transplant donor source infection (2018 edition)[J]. Chin J Organ Transplant, 2018, 39(1):41-52. DOI: 10.3760/cma.j.issn.0254-1785.2018.01.008. [17] AIRES-DE-SOUSA M, ORTIZ DE LA ROSA JM, GONÇALVES ML, et al. Epidemiology of carbapenemase-producing Klebsiella pneumoniae in a hospital, Portugal[J]. Emerg Infect Dis, 2019, 25(9):1632-1638. DOI: 10.3201/eid2509.190656. [18] CAMPOS AC, ALBIERO J, ECKER AB, et al. Outbreak of klebsiella pneumoniae carbapenemase-producing K pneumoniae: a systematic review[J]. Am J Infect Control, 2016, 44(11):1374-1380. DOI: 10.1016/j.ajic. 2016.03.022. [19] COHEN J, MICHOWIZ R, ASHKENAZI T, et al. Successful organ transplantation from donors with acinetobacter baumannii septic shock[J]. Transplantation, 2006, 81(6):853-855. doi: 10.1097/01.tp.0000203804.95180.6e [20] ISON MG, GROSSI P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4):22-30. DOI: 10.1111/ajt.12095. [21] WAN Q, LIU H, YE S, et al. Confirmed transmission of bacterial or fungal infection to kidney transplant recipients from donated after cardiac death (DCD) donors in China: a single-center analysis[J]. Med Sci Monit, 2017, 23:3770-3779. doi: 10.12659/MSM.901884 [22] 陈小松, 韩龙志, 钱永兵, 等.供体来源碳青霉烯酶类耐药肺炎克雷伯杆菌感染--肝肾移植的差异[J/CD].实用器官移植电子杂志, 2018, 6(1): 45-48. DOI: 10.3969/j.issn.2095-5332.2018.01.011.CHEN XS, HAN LZ, QIAN YB, et al. The difference between liver and kidney transplantation--donor derived infection of carbapenemresistant Klebsiella pneumonia[J/CD]. Pract J Organ Transplant (Electr Vers), 2018, 6(1): 45-48. DOI: 10.3969/j.issn.2095-5332.2018.01.011. [23] KARAISKOS I, ANTONIADOU A, GIAMARELLOU H. Combination therapy for extensively-drug resistant gram-negative bacteria[J]. Expert Rev Anti Infect Ther, 2017, 15(12):1123-1140. DOI:10.1080/14787210.2017. 1410434. [24] GARBER K. A β-lactamase inhibitor revival provides new hope for old antibiotics[J]. Nat Rev Drug Discov, 2015, 14(7):445-447. DOI: 10.1038/nrd4666. [25] TUMBARELLO M, TRECARICHI EM, CORONA A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae[J]. Clin Infect Dis, 2019, 68(3):355-364. DOI: 10.1093/cid/ciy492.